Peptide Drug Conjugates Market
Growing Number of Cancer Cases across the globe to push the demand for Peptide Drug Conjugates
Peptide Drug Conjugates Market by Product, Type & Region - Forecast 2023 - 2033
Peptide Drug Conjugates Market Outlook (2023 to 2033)
The global Peptide Drug Conjugates market is anticipated to hold a market value of US$ 861.12 Million in 2023 and US$ 5,331.83 Million by 2033. The projected growth rate is nearly 20% during the forecast period from 2023 to 2033.
The robust clinical trial pipeline with peptide drug conjugates (PDCs) coupled with increase in R&D investments for developing PDCs and rising disease burden across the globe are the factors expected to contribute to the market growth. For instance, in July 2021, Takeda Pharmaceutical Company Limited in collaboration with Peptide Dream, announced to invest USD 3.5 billion to develop peptide drugs for neuromuscular disease.
|
Report Attributes |
Details |
|
Estimated Market Value in 2023 |
US$ 861.12 Million |
|
Estimated Market Value in 2033 |
US$ 5,331.83 Million |
|
Projected CAGR from 2023 to 2033 |
20% |
Let us know your requirement to get
100% FREE customization
Revenue Analysis of Peptide Drug Conjugates Market 2018 to 2022 vs. Future Outlook 2023 to 2033
The global peptide drug conjugates market garnered US$ 717.6 Million in 2022, expanding at a historical CAGR of 16%. Pharmaceutical companies are developing PDCs for metabolic diseases and coronavirus diseases and cancer among others. Currently, the market has two FDA approved drugs Pepaxto (Melflufen) and Lutathera (Lu 177 dotatate) for cancer treatment. Therefore, rising prevalence of such diseases is driving the peptide drug conjugates market. According to the National Cancer Institute, in 2020, more than 1.8 million new cancer cases and more than 600,000 deaths occurred in the U.S. due to cancer.
Due to the increased cancer cases, the pharmaceutical industry has been pushed to investigate additional drug conjugates, resulting in the development and popularity of PDCs. The estimation reveals that the PDCs market is projected to secure a market value of US$ 5,331.83 Million by 2033.
What are the factors boosting the Global Peptide Drug Conjugates Market?
Growing Technological Advancements and Financial Investments to Aid Market Growth
The strong product pipeline and increasing financial investments in research and development is offering lucrative opportunities for the peptide drug conjugates market growth. For instance, AngioChem, Inc.’s product candidate- ANG1005 indicated for brain tumor is undergoing phase 3 clinical studies, Bicycle Therapeutics pipeline products- BT5528&BT1718 indicated for non-small cell carcinoma, are under phase 2 clinical trials. Hence, the expected new PDC approval for treatment of multiple types of cancer will boost the market growth in near future.
According to the national cancer institute, there are more than 250 FDA approved chemotherapeutic drugs used in the treatment of malignant tumors. However, the major drawback associated with such small molecules is uncontrolled toxicity resulting in severe side effects. Moreover, increasing drug resistance of tumor cells to such agents has led to demand for the better treatment approach like targeted PDCs and thereby, driving the peptide drug conjugates space.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Possible Challenges of the Market?
Increasing Costs to Hinder Market Growth
Low bioactivity, poor stability, long research and development time, and slow clinical development process as therapeutic agents of PDC is expected to restrain the segment, leading to increase in overall time and cost incurred for the development.
Country-Wise Analysis
What is the Contribution of North America in Increasing Demand?
Presence of Key Players in the Region to Increase Consumer Demand
North America dominated the overall peptide drug conjugates (PDCs) market in terms of revenue share of 45.6% in 2022, owing to the launch of Melflufen and rapid uptake of PDC drugs in cancer therapy.
Increasing awareness about current treatment options, favorable reimbursement policies, and improved patient affordability are the factors expected to drive the market growth. Furthermore, rising cases of cancer and related mortality is fueling the market growth in the region. For instance, NCI reported approximately 1,806,590 new cancer cases and 606,520 disease related deaths in 2020.
What is the Growth Outlook for Peptide Drug Conjugates in Asia Pacific?
Increasing Investments to Develop PDCs to Boost Regional Market
Asia Pacific is expected to witness a growth rate of 27.4% during the forecast period. Growth of the region is attributed to the upsurge in the number of cancer cases and strategic initiatives undertaken by the market players for regional expansion in such regions. Furthermore, rising research and development along with increasing investments to develop and commercialize such novel delivery systems is anticipated to boost the market growth in the region.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-Wise Insights
Which Type of Product is Boosting the Growth of the Market?
Lutathera Product Segment to Dominate the Category
The Lutathera product segment dominated the peptide drug conjugates market with a revenue share of 80.5% in 2022. The first FDA approved PDC is Novartis’s Lutathera (lutetium Lu 177), a radio labeled somatostatin analog which is an advanced accelerator injection. The expected patent expiry date is 25th July 2038. It is indicated for the treatment of somatostatin receptor-positive gastro enteropancreatic neuroendocrine tumors including foregut, midgut, and hindgut neuroendocrine tumors in adults. Lutathera consists of an amide linkage between homing peptide somatostatin and cytotoxic radiotherapeutic agent 177Lu.
Oncopeptides ABreceived FDA approval for its first-in-class peptide-conjugated alkylator, Pepaxto (melflufen), in February 2021. The combination of Pepaxto (Melphalan flufenamide) with dexamethasone is indicated for the multiple myeloma in adult patients. The drug has demonstrated anti-myeloma activity in myeloma tumor cells resistant to bortezomib and the alkylator melphalan. Melflufen patents cover major markets in the US, Japan, Canada, and Europe. However, the drug has been withdrawn from the U.S. market in October 2021, based on overall survival data from its phase 3 study.
By Type, Which Segment is Propelling the Market Growth?
Therapeutic Segment Leads the Type Segment and is Projected to Dominate the Market
Therapeutic agents of PDC dominated the peptide drug conjugates market with the revenue share of 82.3% in 2022 and is anticipated to witness the fastest growth. The factors attributing to dominance is the presence of both approved PDCs, Lutathera and Pepaxtoas therapeutic agents targeting tumor cells. Moreover, the presence of targeting therapeutic drugs such as ANG1005,
BT5528 and BT1718 under clinical trials are expected to boost the market during the forecast period. Along with cancer, pharmaceutical companies are developing targeting therapeutic PDCs for metabolic diseases and coronavirus diseases due to the significant benefits of PDCs in the therapeutic segment.
PDCs coupled with radionuclides, can also act as diagnostic agents. For example, Mallinckrodt Pharmaceuticals’ In-DTPA-octreotide (octreoscan) which contains radioactive nucleotides, primarily used in localization of neuroendocrine tumors. Furthermore, development and applications of PDCs in diagnosis is anticipated to offer remunerative opportunities for the segment growth.
Competitive Landscape
The players of the market are focusing to increase their global influence and adopt strategies such as; acquisition, collaboration, and partnerships. Key players in the market include Novartis AG; Bicycle Therapeutics; AstraZeneca; Cybrexa Therapeutics; Oncopeptides AB; Angiochem Inc.; Innovasium Soricimed Biopharma; and Theratechnologies. Some of the recent key developments among key players are:
- In November 2022, Cybrexa Therapeutics and Exelixis, Inc. announced the collaboration agreement providing Exelixis the right to acquire, first-in-class peptide-drug conjugate (PDC), CBX-12. This initiative is expected to expand its clinical pipeline for targeted drug therapy.
- In December 2021, Coherent Biopharma and WuXi STA announced the strategic partnership agreement to develop their current and future therapeutic drugs including peptide drug conjugates.
Peptide Drug Conjugates Market- Report Scope
|
Report Attributes |
Details |
|
Market Value in 2023 |
US$ 861.12 Million |
|
Market Value in 2033 |
US$ 5,331.83 Million |
|
Forecast Period |
2023-2033 |
|
Historical Data |
2018-2022 |
|
Quantitative Units |
US$ Million for Value and CAGR from 2023 to 2033 |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Segments Covered |
|
|
Key Companies Profiled |
|
|
Pricing |
Available upon Request |
Key Market Segments Covered in the Global Peptide Drug Conjugates Market
By Product:
- Lutetium
- Melflufen
- ANG1005
- BT1718
- CBX-12
- Other Pipeline Products
By Type:
- Therapeutic Peptide Drug Conjugates
- Diagnostic Peptide Drug Conjugates
By Region:
- North America Peptide Drug Conjugates Market
- Latin America Peptide Drug Conjugates Market
- Europe Peptide Drug Conjugates Market
- Asia Pacific Peptide Drug Conjugates Market
- Middle East & Africa Peptide Drug Conjugates Market
Frequently Asked Questions
North America will account for a major share of global Peptide Drug Conjugates demand.
From 2023 to 2033, the market is projected to expand at a 20% value CAGR, as per FMI.
By 2033, Peptide Drug Conjugates market demand is expected to reach US$ 5,331.83 Million.
By 2023, demand for Peptide Drug Conjugates is forecast to be valued at US$ 861.12 Million
As of 2022, the market for Peptide Drug Conjugates was valued at US$ 717.6 Million
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018-2022 and Forecast, 2023-2033
4.1. Historical Market Size Value (US$ Mn) Analysis, 2018-2022
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2023-2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Product
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Product, 2018-2022
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Product, 2023-2033
5.3.1. Lutetium
5.3.2. Melflufen
5.3.3. ANG1005
5.3.4. BT1718
5.3.5. CBX-12
5.3.6. Other Pipeline Products
5.4. Y-o-Y Growth Trend Analysis By Product, 2018-2022
5.5. Absolute $ Opportunity Analysis By Product, 2023-2033
6. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Type, 2018-2022
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Type, 2023-2033
6.3.1. Therapeutic
6.3.2. Diagnostic
6.4. Y-o-Y Growth Trend Analysis By Type, 2018-2022
6.5. Absolute $ Opportunity Analysis By Type, 2023-2033
7. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2018-2022
7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2023-2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018-2022 and Forecast 2023-2033, By Country
8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Product
8.2.3. By Type
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Product
8.3.3. By Type
8.4. Key Takeaways
9. Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Product
9.2.3. By Type
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product
9.3.3. By Type
9.4. Key Takeaways
10. Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. U.K.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Product
10.2.3. By Type
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product
10.3.3. By Type
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018-2022 and Forecast 2023-2033, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Product
11.2.3. By Type
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product
11.3.3. By Type
11.4. Key Takeaways
12. MEA Market Analysis 2018-2022 and Forecast 2023-2033, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Product
12.2.3. By Type
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product
12.3.3. By Type
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. U.S.
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Product
13.1.2.2. By Type
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Product
13.2.2.2. By Type
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Product
13.3.2.2. By Type
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Product
13.4.2.2. By Type
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Product
13.5.2.2. By Type
13.6. U.K.
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Product
13.6.2.2. By Type
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Product
13.7.2.2. By Type
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Product
13.8.2.2. By Type
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Product
13.9.2.2. By Type
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Product
13.10.2.2. By Type
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Product
13.11.2.2. By Type
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Product
13.12.2.2. By Type
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Product
13.13.2.2. By Type
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Product
13.14.2.2. By Type
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Product
13.15.2.2. By Type
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Product
13.16.2.2. By Type
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Product
13.17.2.2. By Type
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Product
13.18.2.2. By Type
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Product
13.19.2.2. By Type
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Product
13.20.2.2. By Type
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Product
14.3.3. By Type
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Novartis AG
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Oncopeptides AB
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Bicycle Therapeutics
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. AstraZeneca
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Cybrexa Therapeutics
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Angiochem Inc.
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Innovasium Soricimed Biopharma
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Theratechnologies
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Coherent Biopharma
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. WuXi STA
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2018-2033
Table 2: Global Market Value (US$ Mn) Forecast by Product, 2018-2033
Table 3: Global Market Value (US$ Mn) Forecast by Type, 2018-2033
Table 4: North America Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 5: North America Market Value (US$ Mn) Forecast by Product, 2018-2033
Table 6: North America Market Value (US$ Mn) Forecast by Type, 2018-2033
Table 7: Latin America Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 8: Latin America Market Value (US$ Mn) Forecast by Product, 2018-2033
Table 9: Latin America Market Value (US$ Mn) Forecast by Type, 2018-2033
Table 10: Europe Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 11: Europe Market Value (US$ Mn) Forecast by Product, 2018-2033
Table 12: Europe Market Value (US$ Mn) Forecast by Type, 2018-2033
Table 13: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 14: Asia Pacific Market Value (US$ Mn) Forecast by Product, 2018-2033
Table 15: Asia Pacific Market Value (US$ Mn) Forecast by Type, 2018-2033
Table 16: MEA Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 17: MEA Market Value (US$ Mn) Forecast by Product, 2018-2033
Table 18: MEA Market Value (US$ Mn) Forecast by Type, 2018-2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Mn) by Product, 2023-2033
Figure 2: Global Market Value (US$ Mn) by Type, 2023-2033
Figure 3: Global Market Value (US$ Mn) by Region, 2023-2033
Figure 4: Global Market Value (US$ Mn) Analysis by Region, 2018-2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023-2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023-2033
Figure 7: Global Market Value (US$ Mn) Analysis by Product, 2018-2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Product, 2023-2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Product, 2023-2033
Figure 10: Global Market Value (US$ Mn) Analysis by Type, 2018-2033
Figure 11: Global Market Value Share (%) and BPS Analysis by Type, 2023-2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by Type, 2023-2033
Figure 13: Global Market Attractiveness by Product, 2023-2033
Figure 14: Global Market Attractiveness by Type, 2023-2033
Figure 15: Global Market Attractiveness by Region, 2023-2033
Figure 16: North America Market Value (US$ Mn) by Product, 2023-2033
Figure 17: North America Market Value (US$ Mn) by Type, 2023-2033
Figure 18: North America Market Value (US$ Mn) by Country, 2023-2033
Figure 19: North America Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 22: North America Market Value (US$ Mn) Analysis by Product, 2018-2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Product, 2023-2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Product, 2023-2033
Figure 25: North America Market Value (US$ Mn) Analysis by Type, 2018-2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Type, 2023-2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Type, 2023-2033
Figure 28: North America Market Attractiveness by Product, 2023-2033
Figure 29: North America Market Attractiveness by Type, 2023-2033
Figure 30: North America Market Attractiveness by Country, 2023-2033
Figure 31: Latin America Market Value (US$ Mn) by Product, 2023-2033
Figure 32: Latin America Market Value (US$ Mn) by Type, 2023-2033
Figure 33: Latin America Market Value (US$ Mn) by Country, 2023-2033
Figure 34: Latin America Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 37: Latin America Market Value (US$ Mn) Analysis by Product, 2018-2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Product, 2023-2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Product, 2023-2033
Figure 40: Latin America Market Value (US$ Mn) Analysis by Type, 2018-2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Type, 2023-2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023-2033
Figure 43: Latin America Market Attractiveness by Product, 2023-2033
Figure 44: Latin America Market Attractiveness by Type, 2023-2033
Figure 45: Latin America Market Attractiveness by Country, 2023-2033
Figure 46: Europe Market Value (US$ Mn) by Product, 2023-2033
Figure 47: Europe Market Value (US$ Mn) by Type, 2023-2033
Figure 48: Europe Market Value (US$ Mn) by Country, 2023-2033
Figure 49: Europe Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 52: Europe Market Value (US$ Mn) Analysis by Product, 2018-2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Product, 2023-2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Product, 2023-2033
Figure 55: Europe Market Value (US$ Mn) Analysis by Type, 2018-2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by Type, 2023-2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by Type, 2023-2033
Figure 58: Europe Market Attractiveness by Product, 2023-2033
Figure 59: Europe Market Attractiveness by Type, 2023-2033
Figure 60: Europe Market Attractiveness by Country, 2023-2033
Figure 61: Asia Pacific Market Value (US$ Mn) by Product, 2023-2033
Figure 62: Asia Pacific Market Value (US$ Mn) by Type, 2023-2033
Figure 63: Asia Pacific Market Value (US$ Mn) by Country, 2023-2033
Figure 64: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 67: Asia Pacific Market Value (US$ Mn) Analysis by Product, 2018-2033
Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Product, 2023-2033
Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Product, 2023-2033
Figure 70: Asia Pacific Market Value (US$ Mn) Analysis by Type, 2018-2033
Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Type, 2023-2033
Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Type, 2023-2033
Figure 73: Asia Pacific Market Attractiveness by Product, 2023-2033
Figure 74: Asia Pacific Market Attractiveness by Type, 2023-2033
Figure 75: Asia Pacific Market Attractiveness by Country, 2023-2033
Figure 76: MEA Market Value (US$ Mn) by Product, 2023-2033
Figure 77: MEA Market Value (US$ Mn) by Type, 2023-2033
Figure 78: MEA Market Value (US$ Mn) by Country, 2023-2033
Figure 79: MEA Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 82: MEA Market Value (US$ Mn) Analysis by Product, 2018-2033
Figure 83: MEA Market Value Share (%) and BPS Analysis by Product, 2023-2033
Figure 84: MEA Market Y-o-Y Growth (%) Projections by Product, 2023-2033
Figure 85: MEA Market Value (US$ Mn) Analysis by Type, 2018-2033
Figure 86: MEA Market Value Share (%) and BPS Analysis by Type, 2023-2033
Figure 87: MEA Market Y-o-Y Growth (%) Projections by Type, 2023-2033
Figure 88: MEA Market Attractiveness by Product, 2023-2033
Figure 89: MEA Market Attractiveness by Type, 2023-2033
Figure 90: MEA Market Attractiveness by Country, 2023-2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
